ONCT

Oncternal Therapeutics, Inc. (ONCT) | Rumor.io

Oncternal Therapeutics

ONCT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ONCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 26

Oncternal Therapeutics ($ONCT) is set to be delisted on December 3rd with no plans to appeal.
The company's stock has been subject to significant price fluctuations, with some users predicting a potential run-up to at least $20.
There is notable buy volume in $ONCT, with some users anticipating a significant price move.

Generated by AI

Sentiment

Of the messages about ONCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	62.5% -5.1
Bearish	—	—	—	37.5% +5.1

Bullish· Jun 1

The asset is showing a strong uptrend, with a 96.68% increase in price over the past few days, indicating a strong potential for continued growth.
The company is on the verge of a potential buyout, which could lead to a significant increase in stock price.
The asset has a low float of 43.6M shares, which can lead to rapid price movements and make it an attractive option for investors looking to capitalize on momentum.

Bearish· Sep 12

Oncternal Therapeutics has discontinued its clinical trials for its lead drug, ONCT-534, due to lack of clinically meaningful improvements.
The company is exploring strategic alternatives, including monetizing its pipeline assets, which may not be attractive to investors.
Oncternal's management and board of directors may prioritize returning capital to shareholders over pursuing new business opportunities, potentially leading to further declines in the stock price.

Generated by AI

Topics

Of the messages about ONCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Jul 14

Oncternal Therapeutics ($ONCT) has entered into a clinical trial collaboration with Pharmacyclics, an AbbVie company, to advance its Phase 3 study of zilovertamab in combination with ibrutinib for patients with mantle cell lymphoma (MCL).
The collaboration includes the supply of ibrutinib to support the company's global registrational Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory MCL.
The agreement also includes the supply of ibrutinib for a companion study of zilovertamab plus ibrutinib for patients who have progressive disease during the initial four months of ibrutinib monotherapy.

Technical Analysis· Nov 6

$ONCT is in a multiday ascending triangle setup, with a potential breakout above $4.
The stock's chart is primed for a move into the double digits, with key support levels at $3.50 and $3.70.
A close above the volume-weighted average price (VWAP) could set up $ONCT for a potential next move.

Generated by AI

Community

Of the messages about ONCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	68.09%
Newcomers	—	—	—	31.91%

Regulars· Apr 4

The company has discontinued two trials for its lead asset zilovertamab, focusing instead on ONCT-808 in B-cell lymphoma and ONCT-534 in metastatic castration-resistant prostate cancer (mCRPC), with data expected in 2024.
The stock price has fallen significantly, with some analysts expecting it to trade in the range of $0.45 to $0.50 per share if management purchases shares.
The company's cash runway is expected to last until 2025, and some analysts are calling for management to return cash to shareholders rather than continuing to pursue the company's pipeline.

Newcomers· May 31

Newcomers are focused on support and resistance levels for ONCT, with prices to watch at $1.39, $1.30, $1.49, and $1.61.
ONCT has seen a significant increase in price, with a 12.10% rise in the last 20 minutes, and has a float of 43.6M shares with a short float of 4.7%.
ONCT is being considered as a "Penny Stock of the Day" with a potential buy level and target prices, making it a high-risk, high-reward investment opportunity.

Generated by AI

Also Discussed

Investors talking about ONCT also mention

#	Name	Attention
1	BioCryst Pharmaceuticals, Inc.BCRX	0.01%+0
2	GRTS - Gritstone bio, Inc.	——
3	Pavmed Inc.PAVM	0%0
4	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
5	AFMD - Affimed N.V.	——
6	PDS Biotechnology CorporationPDSB	0%-0.01
7	BPMC - Blueprint Medicines Corporation	——
8	Cardiff Oncology Inc.CRDF	0%+0
9	FPAY - FlexShopper, Inc.	——
10	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0